ABIVAX Société Anonyme

ENXTPA:ABVX Stock Report

Market Cap: €486.6m

ABIVAX Société Anonyme Valuation

Is ABVX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ABVX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ABVX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ABVX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ABVX?

Key metric: As ABVX barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ABVX. This is calculated by dividing ABVX's market cap by their current book value.
What is ABVX's PB Ratio?
PB Ratio4x
Book€126.47m
Market Cap€486.65m

Price to Book Ratio vs Peers

How does ABVX's PB Ratio compare to its peers?

The above table shows the PB ratio for ABVX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.6x
OSE OSE Immunotherapeutics
2.4x-72.5%€191.6m
MAAT MaaT Pharma
4.3x0.6%€110.8m
ALSEN Sensorion
2.5x-31.5%€192.2m
VLA Valneva
1.4x4.6%€302.7m
ABVX ABIVAX Société Anonyme
4x2.4%€486.6m

Price-To-Book vs Peers: ABVX is expensive based on its Price-To-Book Ratio (4x) compared to the peer average (2.6x).

Price to Book Ratio vs Industry

How does ABVX's PB Ratio compare vs other companies in the FR Biotechs Industry?

2 CompaniesPrice / BookEstimated GrowthMarket Cap
ALVET TheraVet
0.05xn/aUS$322.59k
ALNEV Neovacs
0.0001xn/aUS$2.96k
No more companies available in this PB range
ABVX 4.0xIndustry Avg. 1.9xNo. of Companies4PB012345+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ABVX is expensive based on its Price-To-Book Ratio (4x) compared to the French Biotechs industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is ABVX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ABVX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ABVX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ABVX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€7.95
€29.18
+267.0%
34.7%€45.00€17.70n/a4
Nov ’25€9.50
€29.18
+207.1%
34.7%€45.00€17.70n/a4
Oct ’25€9.94
€29.18
+193.5%
34.7%€45.00€17.70n/a4
Sep ’25€11.44
€36.34
+217.7%
46.6%€65.00€17.70n/a5
Aug ’25€11.22
€36.34
+223.9%
46.6%€65.00€17.70n/a5
Jul ’25€12.82
€35.74
+178.8%
48.7%€65.00€17.70n/a5
Jun ’25€12.58
€35.74
+184.1%
48.7%€65.00€17.70n/a5
May ’25€14.76
€35.74
+142.1%
48.7%€65.00€17.70n/a5
Apr ’25€13.40
€35.60
+165.7%
49.3%€65.00€17.00n/a5
Mar ’25€12.92
€35.60
+175.5%
49.3%€65.00€17.00n/a5
Feb ’25€12.26
€35.60
+190.4%
49.3%€65.00€17.00n/a5
Jan ’25€9.82
€28.25
+187.7%
38.1%€45.00€17.00n/a4
Dec ’24€9.45
€35.20
+272.5%
48.0%€63.00€17.00n/a5
Nov ’24€9.06
€34.20
+277.5%
50.7%€63.00€17.00€9.505
Oct ’24€15.00
€36.00
+140.0%
45.3%€63.00€17.00€9.945
Sep ’24€17.16
€36.00
+109.8%
45.3%€63.00€17.00€11.445
Aug ’24€17.32
€36.00
+107.9%
45.3%€63.00€17.00€11.225
Jul ’24€15.60
€36.00
+130.8%
45.3%€63.00€17.00€12.825
Jun ’24€18.46
€33.70
+82.6%
52.8%€63.00€15.50€12.585
May ’24€15.10
€33.70
+123.2%
52.8%€63.00€15.50€14.765
Apr ’24€6.95
€26.00
+274.1%
44.8%€45.00€14.00€13.404
Mar ’24€6.51
€48.00
+637.3%
49.6%€81.00€14.00€12.924
Feb ’24€6.97
€49.30
+607.3%
44.6%€81.00€19.20€12.264
Jan ’24€6.18
€49.30
+697.7%
44.6%€81.00€19.20€9.824
Dec ’23€7.25
€49.30
+580.0%
44.6%€81.00€19.20€9.454
Nov ’23€7.58
€49.30
+550.4%
44.6%€81.00€19.20€9.064

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Sanofi

€115.5b

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.

SAN

€92.10

7D

1.4%

1Y

7.8%

Eurofins Scientific

€8.9b

Provides various analytical testing and laboratory services worldwide.

ERF

€46.96

7D

1.3%

1Y

-12.0%

Theranexus Société Anonyme

€3.8m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

ALTHX

€0.49

7D

-2.2%

1Y

-57.3%